Cytosorbents Corporation
CTSOHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and. At a $16.6M market cap, Cytosorbents Corporation ranks as a micro-cap company within healthcare. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Market Cap
$16.6M
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-5.07
EPS (Fwd)
$0.00
ROE
-336.2%
ROA
-17.1%
Cash
$4.4M
Total Debt
$29.4M
Free CF
-$3.5M
52W Change
-69.0%
Annual Financials
Cash vs Debt
Where CTSO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CTSO finished 42.06% below its 150-day moving average ($8.56) and 49.80% below its 200-day moving average ($9.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTSO overbought or oversold?
At the October 20, 2026 close, CTSO's RSI(14) was 63.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CTSO has $4.4M in cash with $29.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$3.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -336.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $29.4M (2022) to $37.1M (2025), reflecting a 26% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CTSO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.